Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...
Industries
Life Sciences Antitrust & Competition
CRA’s life sciences litigation support services are grounded in a comprehensive understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 30 years, our experts have consulted with major life science companies, law firms, and regulatory agencies around the globe. We provide clients with the industry and analytical expertise needed to solve our clients’ most complex issues.
Engagements
- 01CRA assesses class certification, market power, anticompetitive impact, and damages in alleged "No-AG" pay-for-delay suitCRA is retained by a major pharmaceutical manufacturer and a generic first filer in a suit alleging a pay-for-delay settlement. Rather than alleging a cash...View engagement
- 02CRA assesses pharmaceutical supply agreements for potential competitive benefitsA manufacturer of a Schedule II product entered into sequential patent settlement agreements that included product supply obligations. Following allegations...View engagement
- 03CRA conducts market definition analysisCRA was retained by Defendants in this pay-for-delay litigation that went to trial. Plaintiffs included direct purchasers, indirect purchasers, and opt-out...View engagement